Cargando…

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response

The serine/threonine kinase Nek2 is commonly found upregulated in a wide variety of neoplasms including diffuse large B cell lymphoma and multiple myeloma. High expression of Nek2 is implicated in the induction of chromosomal instability, promotion of cell proliferation, and drug resistance in tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Zhimin, Zhou, Wen, Huang, Junwei, Yang, Ye, Wendlandt, Erik, Xu, Hongwei, He, Xiao, Tricot, Guido, Zhan, Fenghuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251609/ https://www.ncbi.nlm.nih.gov/pubmed/25485281 http://dx.doi.org/10.1155/2014/621082

Ejemplares similares

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

Role of NEK2A in Human Cancer and Its Therapeutic Potentials
por: Xia, Jiliang, et al.
Publicado: (2015)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

NEK7 promotes gastric cancer progression as a cell proliferation regulator
por: Li, Yi-Ke, et al.
Publicado: (2021)

NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma
por: Xia, Jiliang, et al.
Publicado: (2020)

Mitotic Regulation by NEK Kinase Networks
por: Fry, Andrew M., et al.
Publicado: (2017)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
por: Hao, M, et al.
Publicado: (2017)

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
por: Shi, Lei, et al.
Publicado: (2010)

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017)

Kinase Inhibitor Profile for Human Nek1, Nek6, and Nek7 and Analysis of the Structural Basis for Inhibitor Specificity
por: Moraes, Eduardo Cruz, et al.
Publicado: (2015)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

An Autoinhibitory Tyrosine Motif in the Cell-Cycle-Regulated Nek7 Kinase Is Released through Binding of Nek9
por: Richards, Mark W., et al.
Publicado: (2009)

NEK4 kinase regulates EMT to promote lung cancer metastasis
por: Ding, Nian‐Hua, et al.
Publicado: (2018)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Nek5: a new regulator of centrosome integrity
por: Prosser, Suzanna L., et al.
Publicado: (2015)

Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization
por: Haq, Tamanna, et al.
Publicado: (2015)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Insights into the Conformational Variability and Regulation of Human Nek2 Kinase
por: Westwood, Isaac, et al.
Publicado: (2009)

Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021)

MiR-486-5p negatively regulates oncogenic NEK2 in hepatocellular carcinoma
por: Fu, Shun-Jun, et al.
Publicado: (2017)

Characterization of the Human NEK7 Interactome Suggests Catalytic and Regulatory Properties Distinct from Those of NEK6
por: de Souza, Edmarcia Elisa, et al.
Publicado: (2014)

The Microtubule Regulator NEK7 Coordinates the Wiring of Cortical Parvalbumin Interneurons
por: Hinojosa, Antonio Jesús, et al.
Publicado: (2018)

NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas
por: Jian, Fangfang, et al.
Publicado: (2021)

NEK8 regulates colorectal cancer progression via phosphorylating MYC
por: Cao, Beibei, et al.
Publicado: (2023)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development
por: Dana, Dibyendu, et al.
Publicado: (2022)

Physiological and Pathological Roles of Mammalian NEK7
por: Sun, Zhenzhen, et al.
Publicado: (2020)

New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing
por: Basei, Fernanda Luisa, et al.
Publicado: (2015)

Integrative Analysis of the Expression Levels and Prognostic Values for NEK Family Members in Breast Cancer
por: Gao, Wen-Liang, et al.
Publicado: (2022)

NEK2 serves as a prognostic biomarker for hepatocellular carcinoma
por: Li, Gang, et al.
Publicado: (2017)

Preparation of an anti-NEK2 monoclonal antibody and its application in liver cancer
por: Chen, Qiuli, et al.
Publicado: (2021)

NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway
por: Xiang, Jianyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3sc890icu23snbk6sd2g1eqg42